|

FKC288 Clinical Trials

2 actively recruiting trials

Pipeline

Phase 1: 2

Top Sponsors

  • Nanjing University School of Medicine2

Indications

  • Membranous Nephropathy - PLA2R Induced1
  • ANCA Associated Vasculitis1
  • IgG4-Related Diseases1
  • Lupus Nephritis1
  • Light Chain Amyloidosis1

Other2 trials

FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Phase 1
The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.